CRVS Stock Analysis: Buy, Sell, or Hold?
CRVS - Corvus Pharmaceuticals, Inc.
$14.09
-0.37 (-2.56%)
âŧ
5d:
-5.5%
30d:
+7.8%
90d:
+11.74%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CRVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRVS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRVS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRVS is currently trading at $14.09, which is considered fair relative to its 30-day fair value range of $13.40 to $14.80.
Technical Outlook: Technically, CRVS is showing sideways momentum. Immediate support is located at $13.60, while resistance sits at $15.72.
Market Sentiment: CRVS scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.14 (+135.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRVS is showing sideways momentum. Immediate support is located at $13.60, while resistance sits at $15.72.
Market Sentiment: CRVS scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.14 (+135.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$13.40 -
$14.80
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
Protect Your Profits
Holding CRVS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 135.2% below Wall St target ($33.14)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.40 -
$14.80
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$1.37
(9.7%)
Support & Resistance Levels
Support Level
$13.60
Resistance Level
$15.72
Current Trend
Sideways
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.20
Wall Street Target
$33.14
(+135.2%)
Share & Embed Analysis
Last updated: August 24, 2026 5:59 PM ET
Data refreshes hourly during market hours. Next update: 6:59 PM
Data refreshes hourly during market hours. Next update: 6:59 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 38 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 39 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 50 HOLD |
Advanced CRVS Option Strategies
Professional options setups generated by AI based on today's CRVS price and gamma walls.
